Abstract
Objective:
Systemic fungal infections have high mortality, and therapy is often toxic. Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a better alternative to typical therapy for Candida krusei.
Design:
Case report.
Setting:
Multidisciplinary intensive care unit (ICU) of a community teaching hospital.
Patient:
A 22-yr-old male with acute lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphotericin B.
Interventions:
Caspofungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with standard ICU care.
Results:
Survival without toxicity from therapy.
Conclusion:
Efficacy of caspofungin acetate in a patient with life-threatening Candida Krusei infection.
MeSH terms
-
Adult
-
Amphotericin B / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Antifungal Agents / therapeutic use*
-
Candida / classification
-
Candidiasis / diagnosis
-
Candidiasis / drug therapy*
-
Candidiasis / etiology
-
Caspofungin
-
Echinocandins
-
Fluconazole / therapeutic use
-
Fungemia / diagnosis
-
Fungemia / drug therapy*
-
Fungemia / etiology
-
Humans
-
Infusions, Intravenous
-
Lipopeptides
-
Male
-
Neutropenia / chemically induced
-
Neutropenia / complications
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / drug therapy*
-
Opportunistic Infections / etiology
-
Peptides*
-
Peptides, Cyclic*
-
Pleural Effusion / diagnosis
-
Pleural Effusion / drug therapy*
-
Pleural Effusion / etiology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides
-
Peptides, Cyclic
-
Amphotericin B
-
Fluconazole
-
Caspofungin